PMID- 19768755
OWN - NLM
STAT- MEDLINE
DCOM- 20091201
LR  - 20091019
IS  - 1097-4598 (Electronic)
IS  - 0148-639X (Linking)
VI  - 40
IP  - 5
DP  - 2009 Nov
TI  - Consensus statement: the use of intravenous immunoglobulin in the treatment of 
      neuromuscular conditions report of the AANEM ad hoc committee.
PG  - 890-900
LID - 10.1002/mus.21433 [doi]
AB  - Intravenous immunoglobulin (IVIG) is a therapeutic biologic agent that has been 
      prescribed for over two decades to treat various neuromuscular conditions. Most 
      of the treatments are given off-label, as little evidence from large randomized 
      trials exists to support its use. Recently, IGIV-C has received an indication for 
      the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). 
      Because of the lack of evidence, an ad hoc committee of the AANEM was convened to 
      draft a consensus statement on the rational use of IVIG for neuromuscular 
      disorders. Recommendations were categorized as Class I-IV based on the strength 
      of the medical literature. Class I evidence exists to support the prescription of 
      IVIG to treat patients with Guillain-Barre syndrome (GBS), CIDP, multifocal motor 
      neuropathy, refractory exacerbations of myasthenia gravis, Lambert-Eaton 
      syndrome, dermatomyositis, and stiff person syndrome. Treatment of Fisher 
      syndrome, polymyositis, and certain presumed autoimmune neuromuscular disorders 
      is supported only by Class IV studies, whereas there is no convincing data to 
      substantiate the treatment of inclusion body myopathy (IBM), idiopathic 
      neuropathies, brachial plexopathy, or diabetic amyotrophy using IVIG. Treatment 
      with IVIG must be administered in the context of its known adverse effects. There 
      is little evidence to advise the clinician on the proper dosing of IVIG and 
      duration of therapy.
FAU - Donofrio, Peter D
AU  - Donofrio PD
AD  - American Association of Neuromuscular and Electrodiagnostic Medicine, 2621 
      Superior Drive NW Rochester, MN 55901, USA. peter.d.donofrio@vanderbilt.edu
FAU - Berger, Alan
AU  - Berger A
FAU - Brannagan, Thomas H 3rd
AU  - Brannagan TH 3rd
FAU - Bromberg, Mark B
AU  - Bromberg MB
FAU - Howard, James F
AU  - Howard JF
FAU - Latov, Normal
AU  - Latov N
FAU - Quick, Adam
AU  - Quick A
FAU - Tandan, Rup
AU  - Tandan R
LA  - eng
PT  - Consensus Development Conference
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Muscle Nerve
JT  - Muscle & nerve
JID - 7803146
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Evidence-Based Medicine/standards
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Neuromuscular Diseases/diagnosis/*immunology/*therapy
MH  - Professional Staff Committees/standards
MH  - Randomized Controlled Trials as Topic/standards
MH  - Treatment Outcome
RF  - 112
EDAT- 2009/09/22 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/09/22 06:00
PHST- 2009/09/22 06:00 [entrez]
PHST- 2009/09/22 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 10.1002/mus.21433 [doi]
PST - ppublish
SO  - Muscle Nerve. 2009 Nov;40(5):890-900. doi: 10.1002/mus.21433.